ROR1 and neoplasm: Previous studies of ROR1 inhibitors in tumor cells from other hematological malignancies have indicated the involvement of both WNT non-canonical (PI3K/AKT/mTOR) and WNT canonical (beta-catenin) signaling pathways, as well as downregulation of the intrinsic apoptotic pathway, including cleavage of caspase 3 [12,27,28].